The London Stock Exchange uses cookies to improve its website. The cookies for analytical purposes have already been set. For more details and how to manage cookies, please see our privacy and cookies policy.

AZN ASTRAZENECA PLC ORD SHS $0.25




 Page 3 of 5

Previous | 1 | 2 | 3 | 4 | 5 | Next

Time/Date Code Headline Source Impact
07:00 23-May-2017 AZN Bydureon EXSCEL trial meets T2D safety objective RNS +0.23% Up
07:00 22-May-2017 AZN AZ AGREEMENT WITH RECORDATI FOR SELOKEN IN EUROPE RNS -0.25% Down
15:00 16-May-2017 AZN Director/PDMR Shareholding RNS +5.51% Up
07:00 12-May-2017 AZN IMFINZI SIGNIFICANT PFS - UNRESECTABLE LUNG CANCER RNS +11.25% Up
07:00 10-May-2017 AZN AZ updates on tralokinumab trial in severe asthma RNS +7.94% Up
14:00 02-May-2017 AZN Total Voting Rights RNS -0.89% Down
07:00 02-May-2017 AZN DURVALUMAB RECEIVES US FDA ACCELERATED APPROVAL RNS -0.89% Down
17:30 27-Apr-2017 AZN Result of AGM RNS +0.52% Up
07:00 27-Apr-2017 AZN AstraZeneca: Q1 2017 Results RNS +0.52% Up
13:30 25-Apr-2017 AZN TAGRISSO RECEIVES FULL APPROVAL IN THE EU RNS +1.67% Up
15:00 03-Apr-2017 AZN Total Voting Rights RNS -1.69% Down
07:01 31-Mar-2017 AZN Tagrisso (osimertinib) receives FDA full approval RNS -1.27% Down
07:00 31-Mar-2017 AZN AZ COMPLETES AGREEMENT WITH TERSERA THERAPEUTICS RNS -1.27% Down
16:00 28-Mar-2017 AZN Director/PDMR Shareholding RNS +0.50% Up
15:00 27-Mar-2017 AZN Director/PDMR Shareholding RNS +1.07% Up
07:00 17-Mar-2017 AZN US FDA issues CRL for ZS-9 in hyperkalaemia RNS +1.20% Up
11:00 16-Mar-2017 AZN Notice of AGM RNS +1.24% Up
07:00 15-Mar-2017 AZN LYNPARZA PFS IN BRCA OVARIAN MAINTENANCE THERAPY RNS +1.63% Up
07:00 08-Mar-2017 AZN Filing of Form 20-F with SEC RNS +1.13% Up
14:30 07-Mar-2017 AZN Annual Financial Report RNS +0.85% Up

 Page 3 of 5

Previous | 1 | 2 | 3 | 4 | 5 | Next



Price changes are calculated on the basis of the following formula: [ avg(x) - avg(y)] / avg(y) where:
x = instrument's 7 closing prices after the news has been released
y = instrument's latest 7 closing prices before the news was released, including the day of the release of the news

Please note that the news releases are only one of the multiple factors that could have had an impact on the change in the security’s price over the time period analysed by the News Analysis tool. Where data are insufficient the graph does not show any price change and the table below the graph displays a blank “ - “ next to the line indicating the RNS issue.





Company Information
Updated Monthly
Company address 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, United Kingdom
Company website http://www.astrazeneca....
Market cap(in millions)* £ 65,496.90
Listing/Admission to trading 01 Jun 1993
Trading service SETS
Market Main Market
Listing category Premium Equity Commercial Companies
*The market capitalisation of companies reflects the London listed element only. These figures are approximate and are updated monthly.

Trading Information
20-Oct-17
FTSE index FTSE All-Share,FTSE Eurotop 300,FTSE 350 High Yield,FTSE 100,FTSE 350 (ex IT),FTSE techMARK All-Share,FTSE All-Share (ex IT),FTSE 350
FTSE sector Pharmaceuticals & Biotechnology
FTSE sub-sector Pharmaceuticals
Country of share register GB
Segment SET0
MiFID Status Regulated Market
Exchange market size 500
SEDOL 0989529
ISIN number GB0009895292



ASTRAZENECA share news analysis (AZN)